News :

Michigan Tech Bear Bones Research Gets a Boost

Posted on : July 16, 2008


Michigan Tech Bear Bones Research Gets a Boost

For more information on this story contact:
Email Jennifer Donovan
Phone: 906-487-4521

July 11, 2008—The steady stream of funds supporting the commercialization of Michigan
Tech bone-research technology as a treatment for osteoporosis continues.
The UP Business Capital (UPBC) group, an arm of Northern Initiatives in Marquette,
recently invested $50,000 to help move the venture forward.
“This is equity capital, not a loan,” says James Baker, director of Michigan Tech’s
Technology and Economic
Development office. “They see the promise. They are willing to risk their investment
because there is the potential upside, but there are no guarantees.”
Northern Initiatives is a nonprofit community development corporation that strives to
enhance the regional economy with a simple but ambitious goal—supporting start-up
companies and getting established companies to relocate to the UP.
Baker describes the infusion of money for the bone research as “significant and essential.”
“High-risk financing for technology start-up companies is difficult to get in this region,” he
says. “People are justifiably cautious about speculative bets. But a willingness to take a
calculated risk has grown high-tech economies elsewhere in the country, and we hope to
emulate that.”
It’s an investment in the future, says UPBC’s Kathy Leone, vice president for commercial
loans. “Our goal is to strengthen communities with increased jobs,” she says.
The work centers around technology being developed by Michigan Tech’s Seth Donahue,
associate professor of biomedical engineering. He has isolated a bone-building biomarker
in the blood of black bears, which don’t lose bone strength during hibernation. If humans
were off their feet like that, Baker says, “bones would deteriorate very rapidly and very
noticeably.” Donahue has evaluated the compound and is encouraged; more laboratory tests
are under way.
Donahue’s work has caught the eye and the pocketbook of other backers. Over the last four
years, support has come from the Michigan Universities Commercialization Initiative and
the National Institutes of Health.
“Osteoporosis is a widespread disease,” Baker says. “From a business standpoint, the
upside potential is significant. A lot of companies are pursuing this market, and the
competition is stiff. The prize is big, but the fight is also hard.”
The Apjohn Group in Kalamazoo, Michigan, supports start-up biotech companies,
particularly in pharmaceuticals. The firm has procured the commercial rights to Donahue’s
technology.
Apjohn founded Aursos Inc., a biotechnology company headquartered in Houghton with
7/16/08 5:05 PM
Loading “http://www.admin.mtu.edu/urel-cgi-bin/print.pl?story=698”
Page 2 of 2
http://www.admin.mtu.edu/urel-cgi-bin/print.pl?story=698
operations in Kalamazoo. Donahue is chairman of the advisory board of Aursos, which is
raising money for the initiative and sought the capital from UPBC. Overall, the endeavor
has attracted $500,000.
“It’s seed funding to raise bigger funding,” says Ronald Shebuski, chief scientific officer of
Aursos and a partner with Apjohn.
Shebuski says that principals in the initiative are “very pleased” about the financial support
from UPBC.
“It’s helping us grow the UP economy,” he says. “It’s quite encouraging. We’re very
enthusiastic.”
Shebuski says that all of this collaboration is galvanized around the vision of reaching a
national market —a treatment option for millions of people, especially women, affected by
osteoporosis.
Shebuski believes there’s “a high likelihood” that a mid- to large-sized pharmaceutical
company will acquire this emerging technology.
He compares the initiative to the cholesterol market, which has spawned many products
totaling several billion dollars.
Similarly, he says, “A small part of the osteoporosis market would be significant.”
With that kind of potential, those involved expect to continue to garner support from grants,
angel capital (wealthy investors), matching funds from the state and venture capital.
Michigan Technological University is a leading public research university, conducting
research, developing new technologies and preparing students to create the future for a
prosperous and sustainable world. Michigan Tech offers more than 120 undergraduate and
graduate degree programs in engineering, forestry and environmental sciences, computing,
technology, business and economics, natural and physical sciences, arts, humanities and
social sciences.

Conference Reports, 10th Anniversary C21 BioVentures Napa

Posted on : July 14, 2008

In the area of osteoporosis Aursos announced worldwide partnering opportunities for its lead compound, black bear parathyroid hormone (BB-PTH (1-34)). New to Pharmaprojects, Aursos is a young biotech company based in Michigan which aims to benefit from the evolutionary advantages that allow black bears to hibernate for up to 6 months without loss of bone density. BB-PTH (1-34) is currently in in vivo testing and slated for an IND filing in 2010.

See, http://www.pharmaprojects.com/conference_reports/10thAnniversary_C21BioVenturesNapa_California-may2008.htm for additional conference information.

Lining up to take their shot - Summit in Chicago next week a chance for entrepreneurs to pitch business plans to venture capitalists

Posted on : March 14, 2008

Dan Fisher is pitching biotech venture Aursos, which is developing a new therapy for osteoporosis.

They are among about 50 entrepreneurs scheduled to present business plans Monday and Tuesday at the Midwest Venture Summit. The biennial event, sponsored by the Illinois Venture Capital Association, showcases companies from the region to venture backers from around the nation.

It is an interesting time to try to raise money for a fledgling business. Some homeowners and established businesses can't get loans. Yet venture backers who invest equity in start-ups continue to raise money and look for places to put it, hoping the markets will be in better shape when their ventures are ready to go public.

Despite the sinking economy and a higher ticket price for the event, the summit is expected to draw more participants than in 2006, when 330 turned out, said association director Maura O'Hara. Sponsors have nearly doubled admission this year to $499 ($599 at the door) and expanded the event to two days from one.

Venture capitalist Bob Geras will award the $70,000 Geras Grant to one early-stage company. In addition, the Illinois Department of Commerce and Economic Opportunity will award a $50,000 grant for the best student plan to help the winner to start a company in the state.

The summit's growth spells progress in a region that has struggled to compete for venture money and to keep its entrepreneurs from leaving.

"There's a decent crop of companies that are stable, and even profitable, run by seasoned entrepreneurs," said venture capitalist Mark Glennon of Leo Capital Holdings LLC in Northbrook. "It's not uncommon now to find [local] companies with entrepreneurs that are on at least their second start-ups, some with real successes under their belts."

Presenters at the summit collectively have raised more than $220 million, according to the association. One of the successes is Franklin Park-based Rubicon Technology Inc., which produces sapphire crystals used in energy-efficient light-emitting-diode lighting.

Byron Denenberg, a managing partner at KB Partners LLC in Northbrook, co-led Rubicon's initial round of funding in May 2002.

"The tech market was really in bad shape, but we did envision this was going to be something very big and interesting," Denenberg said. "Maybe the best time to start a business is when things get bad. You don't get so frustrated you're losing a lot of business while you're going through this [start-up] cycle."

In all, his firm has invested about $6.5 million of the approximately $44 million in private money raised by Rubicon, which went public at $14 per share in November. The stock closed Thursday at $27.87. Private backers can't sell their shares until the lockup period expires in May.

Dalal, co-founder and chief executive of 18-month-old ParkWhiz, is hoping this year's summit will help his online venture attract $1 million in equity funding to deepen its Chicago market and expand into New York, Boston and San Francisco.

"We're hoping to generate some enthusiasm and interest," said the 30-year-old, who was a pre-med major before getting bitten by the tech bug. "We've spoken to a lot of the venture capitalists one on one but never in this large a setting, so we're definitely excited about this opportunity."

The stumbling economy doesn't scare him. He thinks tough times will drive cost-conscious visitors to his site to find deals on parking.

Besides, he added, "If you're persistent and you have a good model and execute, you can succeed in any market."

Aursos to present during the 2008 Midwest Venture Summit

Posted on : March 1, 2008

Dan Fisher, CBO of Aursos, will present the company during the March 17, 18 event in Chicago. This is the premier venture conference in the Midwest. Additional information on the summit can be found at www.midwestventuresummit.com

Aursos to receive $100,000 from MEDC

Posted on :

Twenty-two companies along the Interstate-94 corridor will share $5.05 million from a state program targeting retention of Pfizer Inc. assets and talent.

Low-interest loans of between $50,000 and $400,000 went to the companies following approval by the Michigan Strategic Fund board.

A $500,000 also goes to economic development groups Ann Arbor SPARK and Southwest Michigan First in Kalamazoo to bolster the Michigan Innovation Equipment Depot, created last year to distribute equipment donated by Pfizer to state companies.

Some 101 new jobs are expected to be created with the loan proceeds from the state's $8 million Company Formation and Growth Fund, state officials said.

"This new resource will provide new opportunities for Pfizer employees and spark entrepreneurial activity and job creation," Gov. Jennifer Granholm said in a written release.

The MSF board created the fund in June to help communities recover from closure of Pfizer [NYSE:PFE] facilities in Ann Arbor, Holland, Kalamazoo, Plymouth Township and Portage.

Pfizer Jan. 22 said it would cut 2,410 jobs in Michigan by the end of 2008, 2,100 jobs in Ann Arbor alone with shuttering a 2.3 million-square-foot facility.

Loan recommendations were made by a committee composed of representatives of the Michigan Economic Development Corp. and local economic development groups Ann Arbor SPARK, Southwest Michigan First in Kalamazoo and Zeeland-based Lakeshore Advantage.

Each job created qualifies for a potential loan of $50,000, for a maximum of $500,000 per recipient company.

"This is part of a concerted effort to ensure Pfizer scientists continue working and living in Michigan and re-apply their knowledge and expertise to help grow great new Michigan life sciences companies," MEDC President and CEO James C. Epolito said in the agency's announcement.

The MSF in June also awarded $3.4 million from the 21st Century Jobs Fund to turn a former Pfizer research lab in Holland into a bioeconomy research and commercialization center.

Recipients, loans and jobs created
• ADMETRx, Inc.; Kalamazoo; $250,000; 5
• Armune BioScience, Inc.; Kalamazoo; $100,000; 2
• Apjohn Group, L.L.C.; Kalamazoo; $50,000; 1
• Aursos, Inc.; Kalamazoo; $100,000; 2
• AzoRx, Inc.; Kalamazoo; $100,000; 2
• BioSTAT Consultants, Inc.; Portage; $50,000; 1
• Emiliem, Inc.; Kalamazoo; $250,000; 5
• Integrated Nonclinical Development Solutions, Inc.; Ann Arbor; $50,000; 1
• Jasper Clinical Research & Development, Inc.; Kalamazoo; $250,000; 5
• Kalexsyn, Inc.; Kalamazoo; $350,000; 7
• Lycera Corp.; Ann Arbor; $400,000; 8
• MuciMed, Inc.; Kalamazoo; $200,000; 4
• NanoMed Pharmaceuticals, Inc.; Kalamazoo; $250,000; 5
• NanoVir, LLC; Kalamazoo; $100,000; 2
• NephRx Corp.; Kalamazoo; $200,000; 4
• PharmOptima, LLC; Portage; $400,000; 8
• Phrixus Pharmaceuticals, Inc.; Ann Arbor; $350,000; 7
• ProNAi Therapeutics, Inc.; Kalamazoo; $400,000; 8
• Proteos, Inc.; Kalamazoo; $250,000; 5
• SensiGen, LLC; Ann Arbor; $300,000; 6
• TransPharm Preclinical Solutions, LLC; Jackson; $400,000; 8
• Venomix, Inc.; Kalamazoo; $250,000; 5

Source: Michigan Economic Development Corp.

The Wall Street Journal

Posted on : January 9, 2008 8:17 AM

What Do Black Bears Know About Bone Health?
Posted by Jacob Goldstein
blogs.wsj.com/health

Bear Bones
What Hibernating Bears
Can Teach Us About Osteoporosis
By IVAN ORANSKY
online.wsj.com